Phase 2 Multiple Sclerosis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older.
• People diagnosed with relapsing remitting multiple sclerosis (a form of MS where symptoms come and go) who have not taken any disease-modifying treatments in at least the past two years.
• People who have not previously been treated with a type of medication called anti-CD20 therapy, but whose doctor has already planned to start them on this type of treatment for their MS, and who are able to continue on it for the entire duration of the study.
• People who have at least one MS lesion (an area of damage in the brain or spine) measuring at least 10mm across, found during screening scans.

Who may not be able to join:

• People who have taken corticosteroid medications (a type of anti-inflammatory drug) within the 30 days before screening.
• People who are unable or unwilling to have MRI scans, including those with certain medical devices such as a heart pacemaker or certain types of metal clips in the brain.
• People with poorly controlled high blood pressure, specifically a top reading above 160 or a bottom reading above 110 — though the trial site may consider whether adding blood pressure medication brings these levels under control (confirm with trial site).
• People with moderate to severe heart failure (classified as New York Heart Association Class II or higher).
• People with a notable history of abnormal heart rhythm readings on an ECG, including a condition called QT prolongation, or a family history of a heart rhythm disorder called prolonged QT syndrome.
• People who have had a heart attack within the six months before joining the study.
• People who are pregnant, because the study drug may carry an unknown risk to an unborn baby. People who could potentially become pregnant will need to take a urine pregnancy test before taking part in the study scans.
• People who are currently breastfeeding or chestfeeding, because the study drug may carry an unknown risk to a nursing child. The trial site advises that breastfeeding or chestfeeding should be stopped before the study drug is given.
• People with a known allergy or sensitivity to the study drug (HP 13C pyruvate) or any of its ingredients.
• People with a history of cancer within five years of joining the study, or a history of chemotherapy treatment within two years of joining.
• People who have dental braces or any permanent or non-removable metal in the jaw or face.
• People with serious ongoing medical conditions affecting the heart, metabolism, blood, liver, immune system, kidneys, hormones, lungs, mental health, skin, or other major body systems, where the lead researcher judges these could affect the safety of the participant or make the study results harder to interpret.
• People with any health condition or personal circumstance that, in the researcher's opinion, would make it difficult for them to follow the study procedures.
• People with reduced kidney function (a filtration rate below 60 mL/min/1.73 m²) at their first study visit or later visits, a history of kidney disease, or a known allergy to the contrast dye (gadolinium) used in MRI scans.
• People with an MS disability score above 6.5 on a standard clinical scale (confirm with trial site for details on this measure).

Important: Always verify eligibility with the trial site directly before applying.